Retinoic acid (RA), through nuclear retinoid receptors, regulates the expression of numerous genes. However, little is known of the biochemical mechanisms that regulate RA concentration in vivo. CYP26 (P450RAI), a novel cytochrome P450, is expressed during embryonic development, induced by all-trans RA, and capable of catalyzing the oxidation of 
for two families of ligand-activated nuclear retinoid receptors, RAR and RXR, which regulate the transcription of a large number of genes. Despite many advances in understanding retinoid receptor biology (1) (2) (3) , the regulation of retinoid molecules is not well understood.
The liver is a principal site of retinoid metabolism. Dietary vitamin A, absorbed mainly as esterified retinol, is transported from the intestine to liver by chylomicra and cleared rapidly into hepatocytes (4 -6) . Within these cells, retinyl esters are hydrolyzed and the retinol thus formed is subject to several potentially competing metabolic pathways. Retinol may be re-esterified for storage in hepatocytes and stellate cells, secreted into plasma bound to retinol binding protein, or sequentially oxidized to form retinal and RA (6, 7) . Liver cytosol contains retinol and retinoic acid binding proteins that participate in retinoid metabolism (8, 9) , whereas liver microsomes and cytosol contain members of several families of retinoid dehydrogenases and oxidases capable of oxidizing retinol and retinal and producing RA (10 -13) . RA either derived endogenously or administered exogenously may be oxidized to form more polar metabolites (14) . The majority of exogenously administered RA was rapidly excreted (15, 16) and both unchanged RA and polar metabolites were recovered in the bile of bile duct-cannulated rats and the perfusate of isolated perfused rat liver (15, 17) . Less is understood of the fate of endogenously produced RA, which is formed by the metabolism of vitamin A precursors and is present in cells and plasma at only nanomolar concentrations (11) .
Catabolism appears to play a major role in limiting RA concentration (14) . In 1980, Roberts et al. (18) demonstrated the sequential conversion of RA to 4-hydroxy-and 4-oxo-RA by hamster liver microsomes. The involvement of a cytochrome P450-dependent pathway in RA metabolism was inferred by the biochemical properties of the oxidative process (18) and by the ability of known cytochrome P450 inhibitors to inhibit RA catabolism in vitro and in vivo (19 -21) . Recently, the nature of RA catabolism was clarified with the cloning of a novel gene, CYP26, which encodes a cytochrome P450-related hydroxylase (22) (23) (24) (25) . CYP26 (22, 25) , also named P450 RA (24) for its RA inducibility, was cloned from regenerating, RA-treated zebra fish fin (25) , murine embryonic stem cells (22) (23) (24) , and a human cDNA library (22) . Although analysis of the CYP26 promoter region has not been published, RAR-␥ and RXR-␣ were implicated in regulating CYP26 gene expression in F9 cells (26) . The transfection of CYP26 cDNA into cell lines (22, 24, 26) resulted in the oxidation of exogenous all-trans RA to products identified as 4-hydroxy-and 4-oxo retinoids, but the metabolism of retinol, retinal, or ␤-carotene was not induced (24) . Transfected cells exhibited reduced sensitivity to RA-induced differentiation and reporter gene trans-activation, implying that RA is inactivated by the action of CYP26 (24) .
Besides being expressed in embryonic stem cells and during development (23, 25, 27) , CYP26 mRNA was detected by reverse transcriptase-polymerase chain reaction (RT-PCR) in adult mouse and human liver, brain, and placenta, but not in several other visceral organs (23) . In mice treated with a high dose (100 mg/kg, i.p.) of all-trans RA, CYP26 expression was induced in liver, but not brain (23) . However, RA metabolism was not studied. Thus, it is still unclear whether CYP26 is involved in RA metabolism under physiological conditions, and no studies of its potential regulation by vitamin A nutritional status have been reported. With this background, the present study was designed to clarify whether the expression of CYP26 and the metabolism of RA are regulated in liver of intact animals under conditions of acute, nontoxic RA treatment and chronic dietary exposure to different levels of vitamin A. We found the expression of CYP26 and RA metabolism to be reduced during vitamin A deficiency, up-regulated by acute treatment with RA, and modulated by chronic dietary exposure to vitamin A. In a chronic dietary model, CYP26 expression was strongly correlated with liver retinol concentration. These results imply a role of CYP26 in normal retinoid metabolism, especially when dietary vitamin A intake and hepatic retinol reserves are elevated.
MATERIALS AND METHODS

Animals
The acute effects of RA treatment were studied in normally fed Balb/C mice or in vitamin A-deficient Lewis rats given a single dose of RA, and the effects of diet and age were investigated in a long-term study of chronic vitamin A status in Lewis rats (28) . In the acute model, mice fed a stock rodent diet received a single i.p. dose of all-trans RA, in dimethyl sulfoxide that equaled either 100 mg/kg body weight according to Ray et al. (23) or 5 mg/kg; 24 h later mice were killed and livers were collected and stored at Ϫ70°C. Rats fed a nutritionally complete semisynthetic diet [AIN-93 (29) ] or the same diet lacking vitamin A received two oral doses of 100 g all-trans RA dissolved in 20 l corn oil or corn oil as placebo 2 days and 18 h before death (30) . In the chronic dietary model, male Lewis rats were raised, as described previously (28) , from the time of weaning until they reached the ages of 2-3 months (designated young), 8 -10 months (middle-aged), or 18 -20 months (old) on a semisynthetic diet (29) containing 0.35 mg retinol equivalents/kg diet (denoted as vitamin A marginal), 4 mg/kg (control), or 50 mg/kg (vitamin A-supplemented) (28) . Body weight, plasma retinol (28), liver total retinol (31) , and various biochemical indices of health status (serum alanine:aspartate aminotransferase, bilirubin, protein, albumin, triglycerides and cholesterol) have been reported for these animals (28) .
RNA isolation and analysis
Total RNA samples from individual livers in each treatment group was pooled (two livers per pool) for isolation of poly(A) ϩ RNA (32) and RT-PCR analysis. Poly(A) ϩ RNA samples (3 g of each sample) were fractionated, transferred, and hybridized with cDNA probes labeled with ␣-32 P-[dCTP] (3000 Ci/mmol) using the Prime-a-Gene labeling kit (Promega, Madison, Wis.) (32) . For CYP26, a 1.7 kbp probe was prepared from a plasmid containing mouse P450RAI cDNA (26) , generously provided by Dr. Martin Petkovich, Queen's University (Kingston, Ont.). After hybridization and washing, blots were exposed to XAR-5 film (Eastman Kodak Co., Rochester, N.Y.) at Ϫ80°C for up to 4 days. After the CYP26 probe was stripped off, membranes were rehybridized with labeled mouse RAR-␥ or RXR-␣ (32) and finally with rat skeletal muscle ␤-actin as a control (32) .
For semiquantitative RT-PCR of CYP26 mRNA, 2 g of the pooled total RNA samples (2 rats/pool) in diethylpyrocarbonate-treated water was denatured with 0.2 g of oligo dT at 70°C for 10 min, cooled on ice, and mixed in a final volume of 20 l with 1ϫ Superscript II buffer (Life Technologies, Inc., Gaithersburg, Md.), 0.5 mM each of dNTP (Promega), and 200 U of Superscript II reverse transcriptase (Life Technologies). The RT reaction tubes were incubated at 42°C for 1 h for first strand synthesis, followed by incubation at 70°C for 15 min to stop the RT reaction. Based on the cDNA sequence of the mouse and human CYP26 (26) , PCR primers were designed to amplify a nucleotide fragment of 213 bp; the forward and reverse primers were 5Ј-TTCTGCAGAT-GAAGCGCAGG-3Ј and 5Ј-TTTCGCTGCTTGTGCGAGGA-3Ј, respectively. Five microliters of the RT reaction (diluted to 100 l) was used in a final volume of 25 l for the PCR reaction, which contained 1ϫ PCR buffer II (PE Applied Biosystems, Foster City, Calif.), 1.5 mM MgCl 2 , 0.25 mM of each dNTP, 0.3 M of each primer, and 0.6 U Gold Taq DNA polymerase (PE Applied Biosystems). The amplification reaction was initiated by incubation of PCR samples at 94°C for 10 min, followed by 35 cycles of 94°C, 30 s; 60°C, 30 s; 72°C, 1 min. The PCR products (10 l) were subjected to electrophoresis in 2% agarose gel, 0.3 g/ml ethidium bromide. Data were scanned and quantified using the NIH Image 1.56 program and Instat 1.11 software (GraphPad Software, San Diego, Calif.).
Preparation of liver microsomes, enzyme assay, and HPLC analysis
Liver microsomes were prepared in 5 ml of 10 mM Tris-HCl, 250 mM sucrose, pH 7.4 (33) , and stored at Ϫ70°C prior to analysis. Retinoic acid metabolizing activity was measured by incubating varying amount of microsomal protein (34) , as noted in figure legends, with 60 nM of (11,12-[ 3 H(N)]-retinoic acid (35.8 Ci/mmol, NEN Life Science Products, Inc., Boston Mass.) in 0.5 ml buffer containing 150 mM KCl, 5 mM MgCl 2 , 50 mM Tris-HCl (pH 7.4), and an NADPH regenerating system (2.5 units of glucose 6-phosphate dehydrogenase, 500 nmol of NADP, and 0.5 mol of glucose-6-phosphate) (35) . The reaction was initiated by adding [ 3 H]RA; after incubation at 37°C for the times specified, the reaction was terminated by the addition of 1 ml ethanol/ 0.025 M potassium hydroxide. The retinol and retinyl ester were first removed by extracting twice in 4 ml of hexane. The ethanolic phase was then acidified with 70 l 5 N HCl and the radiolabeled RA was extracted twice into 4 ml of hexane (36) . Subsequently, 3 H remaining in the aqueous subnatant was measured. For high-performance liquid chromatography (HPLC), chromatographic conditions were as described by Teerlink et al. (37) . The samples from the acidified hexane extracts were concentrated under argon at 37°C and redissolved in 110 l of 95% methanol-5% water-40 mM ammonium acetate, pH 5.75, for injection. Samples were resolved by reverse-phase HPLC on a 3 m 4.6 mm ϫ 15 cm octadecasilyl column (Supelcosil LC-18, Supelco, Bellefonte, Pa.) using a gradient (37) of two mobile phases: A) 40 mM ammonium acetate buffer (pH 5.75) in methanol (50:50 v/v); and B) 100% methanol, beginning with 85% A:15% B, 0.8 ml/min, and increasing to 100% B over 22 min, followed by 100% B for 2 min. Fractions (20 s) were assayed for 3 H content by liquid scintillation spectrometry. 4-Oxo-RA, kindly provided by M. Klaus, Hoffmann-LaRoche (Basel, Switzerland), was used as a standard.
Statistics
Analysis of CYP26 mRNA expression in the chronic study was performed by a 2-factor (diet, age) analysis of variance (ANOVA), followed by a Tukey-Kramer test whether the main effects of diet or age were significant. Group comparisons by diet were made by least-significant difference test (Super-ANOVA, Abacus Concepts, Sunnyvale Calif.).
RESULTS
CYP26 mRNA expression in acute and chronic models of retinoid administration
All-trans RA was administered i.p. to normal mice in doses previously used in this species to induce CYP26 expression (23) (100 mg/kg, ϳ2 mg/mouse).
Northern blots of poly(A)
ϩ RNA were hybridized with a cDNA probe specific for CYP26 (Fig. 1) . Little CYP26 mRNA was detected in control mouse liver (Fig. 1A) , whereas CYP26 was induced slightly by RA at 5 mg/kg and very strongly by 100 mg/kg. These treatments did not affect the expression of ␤-actin mRNA used throughout as a control.
Studies were also conducted in normal and vitamin A-deficient rats treated acutely with a lower dose of RA (two 100 g oral doses, each ϳ0.4 mg/kg body weight given 2 days and 18 h before livers were collected). Similar to mice treated i.p. with much higher doses of RA, CYP26 mRNA was barely detectable in the liver of normal and vitamin A-deficient rats but was strongly induced after treatment with RA (Fig. 1B) .
CYP26 expression was investigated in rats that were Northern blot analysis of CYP26 expression using 3.5 g of poly(A) ϩ RNA/lane probed with 32 P-labeled CYP26 cDNA. A) Mice were killed 24 h after an i.p. injection of either 5 mg/kg or 100 mg/kg of RA. B) Rats that had been raised on either control or vitamin A-deficient diet were killed 18 h after the second of two 100 g oral doses of all-trans RA. C) CYP26 mRNA expression in liver of aging rats with stable, chronic vitamin A status. Poly(A) ϩ RNA from young, middleage and old rats fed either control or vitamin A-supplemented diet were prepared as described in Materials and Methods. Film was exposed for 3 days for control diet rats compared to 18 h for vitamin A-supplemented rats. RNA samples in panels A-C were also probed for ␤-actin mRNA levels as a control (using equal film exposure times). D) Analysis of CYP26 amplicons after RT-PCR amplification of RNA from samples shown in Fig. 1B and from old rats fed vitamin A marginal, control, and supplemented diets.
part of a study of the long-term effects of dietary vitamin A during aging (28) . Rats in this chronic study had been fed from the time of weaning one of three diets that differed in vitamin A content but otherwise were identical and nutritionally complete, designated vitamin A marginal, control, and vitamin A-supplemented diet. At the time of the study rats were 2-3 months (young), 8 -10 months (middleaged), or 20 -22 months (old) of age and their livers had accumulated different concentration of vitamin A, depending on diet and age (31), as noted below. CYP26 mRNA was barely detectable in liver of young control rats (Fig. 1C) . CYP26 expression increased with age in rats fed the control diet. CYP26 mRNA was readily detected in liver of vitamin A-supplemented rats and expression increased with age (young Ͻ middle-aged Ͻold).
Total RNA from selected treatments was subjected to RT-PCR using primers specific for CYP26. Figure  1D compares the CYP26 PCR amplicon from liver of vitamin A-deficient rats before and after treatment with RA and from old rats raised on the vitamin A marginal, control, or vitamin A-supplemented diets. CYP26 mRNA was not detected in liver of vitamin A-deficient rats, but was significantly induced by 18 h after treatment with RA. In the chronic dietary study, CYP26 expression increased in a progressive manner with vitamin A intake (vitamin A marginal Ͻ control Ͻ vitamin A-supplemented). Indeed, the expression of CYP26 in rats fed vitamin A-supplemented diet was similar to that of vitamin A-deficient rats after treatment with all-trans RA (lane 2 vs. lane 5).
RAR-␥ and RXR-␣ were previously implicated in the regulation of CYP26 gene expression based on the level of CYP26 mRNA in RA-treated F9 cells lacking specific retinoid receptors or in wild-type cells treated with receptor-selective retinoids (26) . However, in normal rat liver, RAR-␥ mRNA is very low (32, 38, 39) . To determine whether expression of RAR-␥ or RXR-␣ is correlated with that of CYP26, RAR-␥ and RXR-␣ mRNA were determined by Northern blot analysis. Although transcripts for both of
Retinoic acid metabolism
To compare RA metabolism by livers in which CYP26 expression differed significantly, microsomes from liver of mice and rats, treated either acutely with RA or chronically by diet, were incubated with [ 3 H]RA and an NADPH-generating system. Preliminary studies using microsomes from RA-treated rat liver were conducted to determine suitable in vitro incubation conditions. Figure 2 shows that the production of peak 1 (denoted by an arrow in Fig. 2C ), corresponding to the elution position of 4-oxo-RA, was protein dependent ( Fig. 2A ) and time dependent (Fig. 2B) . The metabolism of [ 3 H]RA was significantly greater in microsomes from RA-treated rats than controls (Fig. 2C) , negligible in heat-inactivated microsomes (Fig. 2C) , dependent on NADPH (not shown), and competed by a 500-fold excess of unlabeled RA (not shown). Besides the main peak 1, two or three other peaks of lesser polarity than 4-oxo-RA but greater polarity than all-trans RA were also seen after RA treatment. Because some of these metabolites are produced sequentially, differences in metabolite profile with time and/or extent of induction of metabolism are to be expected. Metabolites such as 4-hydroxy-RA and RA epoxides would be expected to elute in this region, but these peaks were not further characterized in our study.
The results of standard incubations of microsomes from RA-treated mice and rats and from aging rats fed control and vitamin A-supplemented diets are illustrated in Fig. 3 (Fig. 3A) . However, microsomes from mice treated with 5 and especially 100 mg/kg of RA produced peak 1 and other peaks migrating between 4-oxo-RA and RA. Peak 1 was 3 H]-labeled metabolites were extracted and subjected to analysis by HPLC as described in Materials and Methods. A) The dependence of 4-oxo-RA production (peak 1 on panel C) on microsomal protein (using a 50 min incubation time) and B) time of incubation (200 g protein). C) Typical chromatograms from 200 g of rat liver microsomes from RA-treated rats (diamonds), control rats (squares), and an inactive boiled control (circles). Peak 1 corresponds to the elution position of an 4-oxo-RA standard (arrow); other peaks were observed repeatedly but not identified. The elution time of RA (not shown) was ϳ37 min. substantially induced in both vitamin A-deficient and control rat livers after treatment with RA (Fig. 3B) .
RA metabolism was also studied in liver microsomes from aging rats fed control or vitamin A-supplemented diets (Fig. 3C ). Differences were greatest in livers of vitamin A-supplemented rats, where there was a progressive increase in peak 1 with increasing age (young Ͻ middle-aged Ͻ old). Overall, the metabolism of [ 3 H]RA was nearly fourfold greater in old vitamin A-supplemented vs. old control rats.
The same microsomal incubations were used to determine the conversion of [ 3 H]RA to compounds that remained in the aqueous phase after hexane extraction of acidic retinoids. Aqueous-soluble 3 H counts increased linearly with microsomal protein to ϳ150 g and with time to ϳ90 min (data not shown). However, in contrast to lipid-soluble 3 H metabolites, aqueous-soluble 3 H was nearly equal in incubations from vitamin A-deficient and control rats and differed little after acute RA or chronic dietary treatments. Thus, these metabolites were not well correlated with CYP26 expression or production of lipid-soluble 3 H-RA metabolites.
Relationship of CYP26 mRNA to hepatic total retinol concentration
Analysis of CYP26 mRNA expression was performed by RT-PCR for all groups of rats in the chronic diet study (three pools per treatment with two livers per pool). The results (Fig. 4) are expressed relative to the mean value for the young control group (defined as 1.0); this group was selected for reference because most studies of normal rats have used animals of approximately this age. Values ranged from 0 (undetectable) in most vitamin A marginal rats to three-to fourfold induced relative to the reference group. There were significant main effects for both diet (PϽ0.0001, 2-factor ANOVA) and age (Pϭ0.0003), and a significant interaction (PϽ0.05). Across all diet groups, CYP26 expression differed by age (youngϽmiddle-agedϽold, PϽ0.01, Tukey-Kramer test); across all age groups, CYP26 CYP26 mRNA from livers of rats in the chronic dietary study was amplified by RT-PCR, quantified by densitometry, and normalized to the mean value for the young control-fed group (defined as 1.0), and expressed as the mean Ϯ se for each group (nϭ3 pools/treatment, each pool from 2 rat livers). Within age groups, all differences between diet groups differed; P Ͻ 0.001, by least-significant difference test. Fig. 4) .
Because rats in the chronic dietary study were fed their respective levels of vitamin A throughout life, age may have been a proxy for exposure to vitamin A, which is reflected in the wide range of hepatic vitamin A concentrations among these animals (31) . Therefore, the relationship between CYP26 expression and hepatic retinol concentration was explored by regression analysis (Fig. 5) . There was a strong relationship between hepatic CYP26 mRNA and log 10 total retinol. Based on all data points (nϭ27), there was a significant linear correlation (rϭ0.909, Pϭ0.0001). Since values for rats fed the marginal diet were at or below detection limits, we reanalyzed the data from only the control and vitamin A-supplemented groups. Again there was a significant linear correlation (rϭ0.904, Pϭ0.0001, nϭ18).
DISCUSSION
CYP26 expression
Previous investigations of CYP26 gene expression and enzymatic activity have focused almost entirely on acute regulation in either cell lines (23, 24, 40) or during embryonic development (24, 27) or limb regeneration (25) . A study that investigated CYP26 expression in tissues of adult mice (23) examined gene induction only after mice were treated with a very high dose of all-trans RA (100 mg/kg) and retinoid metabolism was not examined. The principal finding of the present investigation is that CYP26 gene expression is barely expressed in normal adult rodent liver, but is strongly induced not only by acute treatment with RA, including doses lower than previously tested, but by long-term exposure to dietary vitamin A. In rats given no exogenous RA but fed diets differing in vitamin A content from deficient to marginal, control, and supplemented, CYP26 mRNA increased progressively (Fig.  1D) . The level of CYP26 mRNA in liver of old, vitamin A-supplemented rats was nearly equal to that in liver of vitamin A-deficient rats treated with exogenous RA. Thus, either acute retinoid treatment, as may resemble conditions when RA is used therapeutically (see ref 19 for a review), or the chronic exposure to dietary vitamin A at an elevated but nontoxic level induced CYP26 gene expression similarly. In intact animals as compared to cultured cells (26) , the expression of RAR-␥ and RXR-␣ did not correlate with CYP26 expression, suggesting their constitutive expression was sufficient for CYP26 induction. Overall, these data establish that a continuum of CYP26 expression exists in liver under physiologically relevant conditions, varying from no detectable expression in vitamin A deficiency, to minimal expression in animals fed a vitamin A marginal diet, and progressively increasing when dietary vitamin A was at an adequate (control) level. When vitamin A intake is above an adequate level, as in vitamin A-supplemented rats, CYP26 mRNA is upregulated. The extent of up-regulation increased with age, as did liver vitamin A contents (see below). Thus, the induction of CYP26 was maintained as a steady-state adaptation to an elevated intake of vitamin A; this adaptation occurred in the absence of exogenous RA. If we consider the expression of CYP26 in young control-fed rats to represent a normal level of CYP26 expression, the results demonstrate down-regulation or chronic repression in rats fed vitamin A-deficient or marginal diet, as well as chronic induction in vitamin A-supplemented rats. It is plausible that CYP26 regulation provides an important mechanism to conserve the body's endogenously formed RA when the precursor supply of dietary vitamin A is limited and to remove RA when it builds up.
It is important to note that the vitamin A-supplemented diet used in this study did not induce hepatic or systemic toxicity (28) . To test for potential hepatotoxicity, serum alanine:aspartate transaminase, bilirubin, and albumin were analyzed, but these did not differ with dietary treatment and all values were within normal range (28) . The vitamin A-supplemented rats in this study may be a good model for human beings who are chronic users of vitamin/mineral supplements and/or foods such as liver that contain high levels of preformed vitamin A (see ref 28 for a discussion).
RA metabolism
There was a generally good relationship between CYP26 mRNA and RA metabolism when CYP26 was induced in RA-treated mice and rats and vitamin A-supplemented aging rats. One of the retinoid peaks detected, peak 1, comigrated with 4-oxo-RA and therefore is putatively identified as [ 3 H]4-oxo-RA; other peaks were consistent with their being metabolites, such as 4-or 18-hydroxy-RA and retinoid epoxides, which have been identified previously in microsomal incubations (35) or CYP26-transfected, RA-treated cells (24, 25) . Previous nutritional studies showed an increased rate of retinol metabolism and retinoid excretion as dietary vitamin A intake increased (41) . However, neither the scope of RA metabolism nor the biological significance of oxidized retinoids is well understood. RA administered to intact animals is eliminated rapidly from plasma (16) and is excreted in bile in the form of unchanged RA as well as a variety of oxidized metabolites and glucuronide conjugates (17) . But whether metabolites of RA are catabolic end products destined for excretion or perhaps have functional properties in certain situations is still uncertain. In HeLa cells, overexpression of CYP26 reduced the ability of RA to induce the trans-activation of retinoid-responsive promoter elements (24) , suggesting that a function of CYP26 is to induce RA catabolism and thus limit RA's biological activities. On the other hand, RA metabolites may also be bioactive, as exemplified by the restoration of spermatogonial division in 4-oxo-RA-treated vitamin A-deficient mice (42) and by the differentiation of CYP26-transfected, RAtreated P19 cells toward a neuronal phenotype, which was not induced by RA alone (40) . In addition, other cytochrome P450s have been described as being regulated by retinoids (43, 44) or as playing a role in retinoid 4-hydroxylation (45) (46) (47) , which may precede the formation of 4-oxo (keto)-RA (18) . Further studies in different cell types and intact animals are needed to clarify the range and activities of cytochrome P450s involved in retinoid metabolism.
Correlation of CYP26 mRNA with liver retinol
Significant differences in CYP26 expression due to diet and age were apparent from the analysis of data shown in Fig. 4 . Hepatic vitamin A is considered one of the best indicators of vitamin A status (48) . Rats in the chronic dietary study were known to have a very wide range of liver total retinol concentration (31); therefore, it was of interest to determine the range of liver total retinol concentration over which CYP26 expression varied (Fig. 5) . While there was little CYP26 mRNA in any of the vitamin A marginal groups regardless of age or liver vitamin A, CYP26 mRNA increased nearly linearly with the log of liver retinol concentration in control and vitamin A-supplemented rats. It has been inferred from a variety of data that human beings with liver total retinol concentrations Ͻ20 g/g (70 nmol/g) are at risk of vitamin A deficiency (see ref 48) . Indeed, plasma retinol also tends to fall when liver retinol is Ͻ20 g/g (48) . Based on the relationship between CYP26 expression and liver retinol shown in Fig. 5 , CYP26 mRNA expression equal to half that of the mean young control value would correspond to a liver vitamin A concentration of ϳ50 nmol total retinol/g, or 14 g/g. Thus, CYP26 expression is regulated in a range where other biochemical processes indicative of vitamin A status, such as regulation of plasma retinol, are also regulated. The regulation of hepatic CYP26 expression may be an important mechanism for tightly controlling the concentration of RA, a potent hormone, in the face of wide, but still physiological, differences in vitamin A intake and hepatic vitamin A accumulation. In addition, it has been reported that a major portion or even the preponderance of liver RA is derived by uptake from plasma (16) ; this RA presumably represents RA produced in peripheral tissues. Thus the liver, through the regulation of CYP26 expression, may play a central role in regulating RA concentrations throughout the body. If so, then the hepatic regulation of CYP26 expression could, in turn, have farreaching effects on peripheral retinoid concentrations and on retinoid-responsive gene transcription in target tissues as well as within liver.
